Literature DB >> 32980695

Development and validation of a prognostic nomogram to predict recurrence in high-risk gastrointestinal stromal tumour: A retrospective analysis of two independent cohorts.

Yao Lin1, Ming Wang2, Jie Jia1, Wenze Wan1, Tao Wang1, Wenchang Yang1, Chengguo Li1, Xin Chen1, Hui Cao2, Peng Zhang3, Kaixiong Tao4.   

Abstract

BACKGROUND: The risk of recurrence in localised, primary gastrointestinal stromal tumour (GIST) classified as high-risk after complete resection varies significantly. Thus, we aimed to develop a nomogram to predict the recurrence of high-risk GIST after surgery to aid patient selection.
METHODS: We retrospectively evaluated patients (n = 424) with high-risk GIST who underwent curative resection as the initial treatment at two high-volume medical centres, between January 2005 and September 2019. The least absolute shrinkage and selection operator (LASSO) regression model was utilised to select potentially relevant features. Multivariate Cox proportional hazards analysis was used to develop a novel nomogram.
FINDINGS: The nomogram comprised age, fibrinogen levels, prognostic nutritional index (PNI), platelet-lymphocyte ratio (PLR), mitotic counts and tumour size, which provided favourable calibration and discrimination in the training dataset with an AUC of 0•749 and a C-index of 0•742 (95%CI:0•689-0•804). Further, it showed acceptable discrimination in the validation cohort, with an AUC of 0•778 and C-index of 0•735 (95%CI:0•634-0•846). The time-dependant receiver operating characteristic (ROC) curves performed well throughout the observation period. Additionally, the nomogram could classify high-risk GISTs into 'very high-risk' and 'general high-risk' groups with a hazard ratio (HR) of 5•190 (95%CI: 3•202-8•414) and 5•438 (95%CI: 2•236-13•229) for the training and validation datasets, respectively.
INTERPRETATION: The nomogram independently predicted post-operative recurrence-free survival (RFS) in high-risk GIST and showed favourable discrimination and calibration values. It may be a useful clinical tool for identifying 'very high-risk' GIST, by allowing treatment strategy optimisation in these patients. FUNDING: National Natural Science Foundation of China (No. 81702386 and 81874184).
Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Gastrointestinal stromal tumour; High-risk; Nomogram; Prognosis; Recurrence

Mesh:

Substances:

Year:  2020        PMID: 32980695      PMCID: PMC7522759          DOI: 10.1016/j.ebiom.2020.103016

Source DB:  PubMed          Journal:  EBioMedicine        ISSN: 2352-3964            Impact factor:   8.143


  21 in total

1.  Design and Application of a Variable Selection Method for Multilayer Perceptron Neural Network With LASSO.

Authors:  Kai Sun; Shao-Hsuan Huang; David Shan-Hill Wong; Shi-Shang Jang
Journal:  IEEE Trans Neural Netw Learn Syst       Date:  2016-03-30       Impact factor: 10.451

Review 2.  Adjuvant and neoadjuvant imatinib therapy: current role in the management of gastrointestinal stromal tumors.

Authors:  Burton L Eisenberg; Jonathan C Trent
Journal:  Int J Cancer       Date:  2011-12-01       Impact factor: 7.396

3.  X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization.

Authors:  Robert L Camp; Marisa Dolled-Filhart; David L Rimm
Journal:  Clin Cancer Res       Date:  2004-11-01       Impact factor: 12.531

4.  Natural history of imatinib-naive GISTs: a retrospective analysis of 929 cases with long-term follow-up and development of a survival nomogram based on mitotic index and size as continuous variables.

Authors:  Sabrina Rossi; Rosalba Miceli; Luca Messerini; Italo Bearzi; Guido Mazzoleni; Carlo Capella; Gianluigi Arrigoni; Aurelio Sonzogni; Angelo Sidoni; Luisa Toffolatti; Licia Laurino; Luigi Mariani; Vincenza Vinaccia; Chiara Gnocchi; Alessandro Gronchi; Paolo G Casali; Angelo P Dei Tos
Journal:  Am J Surg Pathol       Date:  2011-11       Impact factor: 6.394

5.  Predictive Ability of Blood Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios in Gastrointestinal Stromal Tumors.

Authors:  Jennifer M Racz; Michelle C Cleghorn; M Carolina Jimenez; Eshetu G Atenafu; Timothy D Jackson; Allan Okrainec; Lakshmikumar Venkat Raghavan; Fayez A Quereshy
Journal:  Ann Surg Oncol       Date:  2014-12-04       Impact factor: 5.344

6.  A Novel Pathological Prognostic Score (PPS) to Identify "Very High-Risk" Patients: a Multicenter Retrospective Analysis of 506 Patients with High Risk Gastrointestinal Stromal Tumor (GIST).

Authors:  Xuechao Liu; Haibo Qiu; Zhiming Wu; Peng Zhang; Xingyu Feng; Tao Chen; Yong Li; Kaixiong Tao; Guoxin Li; Xiaowei Sun; Zhiwei Zhou
Journal:  J Gastrointest Surg       Date:  2018-07-20       Impact factor: 3.452

7.  A novel predictor in patients with gastrointestinal stromal tumors: Systemic immune-inflammation index (SII).

Authors:  Ali Yilmaz; Cem Mirili; Mehmet Bilici; Salim Basol Tekin
Journal:  J BUON       Date:  2019 Sep-Oct       Impact factor: 2.533

8.  Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial.

Authors:  Heikki Joensuu; Mikael Eriksson; Kirsten Sundby Hall; Annette Reichardt; Jörg T Hartmann; Daniel Pink; Giuliano Ramadori; Peter Hohenberger; Salah-Eddin Al-Batran; Marcus Schlemmer; Sebastian Bauer; Eva Wardelmann; Bengt Nilsson; Harri Sihto; Petri Bono; Raija Kallio; Jouni Junnila; Thor Alvegård; Peter Reichardt
Journal:  J Clin Oncol       Date:  2015-11-02       Impact factor: 44.544

9.  Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis.

Authors:  Jason S Gold; Mithat Gönen; Antonio Gutiérrez; Javier Martín Broto; Xavier García-del-Muro; Thomas C Smyrk; Robert G Maki; Samuel Singer; Murray F Brennan; Cristina R Antonescu; John H Donohue; Ronald P DeMatteo
Journal:  Lancet Oncol       Date:  2009-09-28       Impact factor: 41.316

10.  Evaluation of high-risk clinicopathological indicators in gastrointestinal stromal tumors for prognosis and imatinib treatment outcome.

Authors:  Wen-Yi Zhao; Jia Xu; Ming Wang; Zi-Zhen Zhang; Lin Tu; Chao-Jie Wang; Hui Cao; Zhi-Gang Zhang
Journal:  BMC Gastroenterol       Date:  2014-06-07       Impact factor: 3.067

View more
  4 in total

1.  Prediction of recurrence-free survival and adjuvant therapy benefit in patients with gastrointestinal stromal tumors based on radiomics features.

Authors:  Fu-Hai Wang; Hua-Long Zheng; Jin-Tao Li; Ping Li; Chao-Hui Zheng; Qi-Yue Chen; Chang-Ming Huang; Jian-Wei Xie
Journal:  Radiol Med       Date:  2022-09-04       Impact factor: 6.313

2.  Development and validation of a novel diagnostic model for initially clinical diagnosed gastrointestinal stromal tumors using an extreme gradient-boosting machine.

Authors:  Bozhi Hu; Chao Wang; Kewei Jiang; Zhanlong Shen; Xiaodong Yang; Mujun Yin; Bin Liang; Qiwei Xie; Yingjiang Ye; Zhidong Gao
Journal:  BMC Gastroenterol       Date:  2021-12-18       Impact factor: 3.067

3.  Postoperative Adjuvant Imatinib Therapy-Associated Nomogram to Predict Overall Survival of Gastrointestinal Stromal Tumor.

Authors:  Xuechao Liu; Enyu Lin; Yuqi Sun; Xiaodong Liu; Zequn Li; Xuelong Jiao; Yi Li; Dong Guo; Peng Zhang; Xingyu Feng; Tao Chen; Zhaojian Niu; Zhiwei Zhou; Haibo Qiu; Yanbing Zhou
Journal:  Front Med (Lausanne)       Date:  2022-03-10

4.  A Survival Prediction for Acute Heart Failure Patients via Web-Based Dynamic Nomogram with Internal Validation: A Prospective Cohort Study.

Authors:  Ting Yin; Shi Shi; Xu Zhu; Iokfai Cheang; Xinyi Lu; Rongrong Gao; Haifeng Zhang; Wenming Yao; Yanli Zhou; Xinli Li
Journal:  J Inflamm Res       Date:  2022-03-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.